SBI Securities’s AN2 Therapeutics ANTX Stock Holding History

SBI Securities’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.07K	Hold	201	–	–	﹤0.01%	2831
2026 Q2	$973	Hold	201	–	–	﹤0.01%	2815
2026 Q1	$687	Buy	201 +1	+0.5%	+$2	﹤0.01%	2783
2025 Q4	$228	Hold	200	–	–	﹤0.01%	3171
2025 Q3	$254	Hold	200	–	–	﹤0.01%	3239
2025 Q2	$212	Hold	200	–	–	﹤0.01%	3286
2025 Q1	$272	Hold	200	–	–	﹤0.01%	3108
2024 Q4	$276	Buy	+200	New	+$243	﹤0.01%	3125

Other funds holding ANTX

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

SBI Securities's ANTX Position: Q3 2026 in Review

SBI Securities held its AN2 Therapeutics (ANTX) position steady in Q3 2026 at 201 shares worth $1.07K. The position accounts for ﹤0.01% of the portfolio, ranked #2831.

SBI Securities first reported a position in ANTX in Q4 2024 and has held it in 8 quarters since. 5 funds tracked by Wall St. Rank hold ANTX as of Q3 2026.

SBI Securities held 201 shares of AN2 Therapeutics worth $1.07K as of Q3 2026.
SBI Securities left its AN2 Therapeutics share count unchanged in Q3 2026.
AN2 Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #2831 holding.
SBI Securities first reported a position in AN2 Therapeutics in Q4 2024 and has held it in 8 quarters since.
5 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.